Clearside Biomedical

Clearside Biomedical is a biopharmaceutical company focused on developing and delivering treatments for serious eye diseases, aiming to restore and preserve vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company employs a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic agents to specific compartments of the eye, such as the retina and choroid. Among its products, XIPERE is a triamcinolone acetonide injectable suspension designed for treating macular edema linked to conditions like uveitis and diabetic macular edema. Additionally, the company's CLS-AX is being developed as an axitinib formulation for suprachoroidal injection. Clearside's innovative approach provides a non-surgical and repeatable method for administering therapies, which could significantly benefit patients with sight-threatening eye diseases.